GlassScriptPhysician profile
Melissa Shipley
NPI 1518057868
$1,177.13
in general payments reported to CMS, 2019-2025
11 companies · $332 in 2025
The $332 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2021: $70.44 · 2022: $228 · 2024: $444 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $213.08 | 2024-2025 | Hydrus Microstent, Rocklatan, Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $185.59 | 2021-2025 | Veritas Vision System, Tecnis Iol, Tecnis Simplicity |
| Rxsight INC | $140.90 | 2022 | |
| Amgen INC. | $124.46 | 2024 | Tepezza |
| Harrow Eye, LLC | $119.50 | 2024-2025 | Vevye |
| Glaukos Corporation | $113.14 | 2022-2024 | Ce-Marked Kxla System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $102.47 | 2019 | |
| Sun Pharmaceutical Industries INC. | $79.56 | 2022-2025 | |
| Dompe US, INC. | $64.88 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $17.73 | 2025 | Xiidra, Miebo |
| Abbvie INC. | $15.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Shipley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.